Search results
Results From The WOW.Com Content Network
Budesonide/formoterol, sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). [2] It contains budesonide , a steroid ; and formoterol , a long-acting β 2 -agonist (LABA). [ 2 ]
Three types of dry powder inhalers: Turbuhaler, Accuhaler and Ellipta devices. A dry-powder inhaler ( DPI ) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma , bronchitis , emphysema and COPD although DPIs (such as inhalable insulin ) have also been ...
In children, a short-acting β 2 adrenergic agonist (e.g., salbutamol) is still recommended. It was patented in 1972 and came into medical use in 1998. [4] It is available as a generic medication. [5] It is also marketed in the combination formulations budesonide/formoterol and mometasone/formoterol.
MDI canister and actuator components from H&T Presspart. A metered-dose inhaler consists of three major components: the canister, which is produced in aluminum or stainless steel by means of deep drawing, where the formulation resides; the metering valve, which allows a metered quantity of the formulation to be dispensed with each actuation; and an actuator (or mouthpiece) which enables the ...
An inhaler (puffer, asthma pump or allergy spray) is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications.
Formulations of delayed-release budesonide are an effective treatment for mild-to-moderately active Crohn's disease involving the ileum and/or ascending colon. [25] A Cochrane review found evidence for up to three months (but not longer) of maintenance of remission in Crohn's disease, concluding that budesonide is not effective for maintenance of remission in CD.
Overuse of β 2 agonists and asthma treatment without proper inhaled corticosteroid use has been associated with an increased risk of asthma exacerbations and asthma-related hospitalizations. [8] The excipients, in particular sulfite , could contribute to the adverse effects.
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).